## Edgar Filing: Bielasz Jennifer Kathleen - Form 4

Bielasz Jenr Form 4 March 30, 2	nifer Kathleen 012									
FOR	OMB APPROVAL									
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	3235-0287	
Check th if no lon	der	U /							January 31,	
subject t Section Form 4 ( Form 5	16. or	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							2005 verage rs per 0.5	
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type	Responses)									
Bielasz Jennifer Kathleen Symbol			er Name and Ticker or Trading A PHARMACEUTICALS				5. Relationship of Reporting Person(s) to Issuer			
		INC [A	RNA]				(Check all applicable)			
(Last)	of Earliest Transaction Day/Year)				Director 10% Owner Officer (give title Other (specify below) below)					
	IA CEUTICALS, INC., IDGE DRIVE	03/29/2	012				Sr.Dir. of A	Acct. & Cont. (I	PAO)	
	endment, Date Original nth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
SAN DIEG	O, CA 92121						Form filed by M Person	ore than One Re	porting	
(City)	(State) (Z	ip) Tab	le I - Non-I	Derivative	Secu	rities Acqu	iired, Disposed of,	or Beneficial	y Owned	
1.Title of Security (Instr. 3)	a	2A. Deemed Execution Date, if my Month/Day/Year)	3. 4. Securities Acquired Transactior(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or				5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount	(D)	Price	(Instr. 3 and 4)			
Common Stock	03/29/2012		М	6,250	А	\$ 1.49	15,600	D		
Common Stock	03/29/2012		S	6,250	D	\$ 3.0401	9,350 <u>(1)</u>	D		
Common Stock	03/29/2012		S	4,550	D	\$ 3.0101	4,800	D		
Common Stock							30	Ι	By son	

### Edgar Filing: Bielasz Jennifer Kathleen - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number onof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 1.49	03/29/2012		М	6,250	(2)	03/15/2021	Common Stock	6,250

# **Reporting Owners**

Reporting Owner Name / Address		Relationships					
	Director	10% Owner		Other			
Bielasz Jennifer Kathleen C/O ARENA PHARMACEUTICALS, INC 6166 NANCY RIDGE DRIVE SAN DIEGO, CA 92121			Sr.Dir. of Acct. & Cont. (PAO)				
Signatures							
Adam S. Chinnock, as Attorney-in-Fact	03/30/2012	2					

Attorney-in-Fact

Date

\*\*Signature of Reporting Person

**Explanation of Responses:** 

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The reporting person paid the issuer a total of \$34.20 for the difference between the \$1.90 per share price of the 30 shares her son (1) purchased on February 1, 2012, and the \$3.0401 per share price of 30 of the shares sold by the reporting person and reported on this line.
- The options, representing the right to purchase a total of 25,000 shares, vest in four equal annual installments beginning on March 15, (2) 2012, which was the first anniversary of the date on which the options were granted. The options are exercisable once vested.

Γ

## Edgar Filing: Bielasz Jennifer Kathleen - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.